超声引导下经皮穿刺抽吸和注射无水乙醇治疗单纯性肾囊肿

目的评价超声引导下经皮穿刺抽吸和注射无水乙醇治疗单纯性肾囊肿的效果。方法46例单纯性肾囊肿患者(男性26例,女性20例,平均年龄65岁)均经超声引导经皮穿刺抽吸和注射无水乙醇硬化治疗。全部操作是在局部麻醉下完成的。治疗后,全部病人经超声或CT随访1至6个月。囊肿与治疗前比较,减小2/3以上为有效,完全消失为治愈。结果46个囊肿中,2个囊肿抽出液蛋白定性试验阴性,抽液后未注入无水乙醇,其余44个囊肿于治后1,3,6个月呈进行性缩小,6个月时复查有效率为100%,治愈率为90.6%。结论超声引导经皮穿刺抽吸和注射无水乙醇是治疗单纯性肾囊肿的一种操作简单、痛苦小、费用低、安全有效的方法,值得临床推广应用。     

CT引导下肾囊肿、卵巢囊肿穿刺硬化治疗的临床应用

目的探讨CT引导下肾囊肿、卵巢囊肿穿刺硬化治疗的临床应用价值。方法在CT引导下经皮穿刺肾囊肿、卵巢囊肿,根据预定方案针尖位于最佳位置后,开始抽吸囊液,抽尽囊液后,按抽出量的25%注入无水乙醇3~5 m in后再抽取囊液,重复此操作3~4次,据囊肿大小注入3~15 m l无水乙醇保留于囊腔,拔针,CT扫描穿刺部位观察有无特殊改变,术后嘱患者辗转体位3~5次使无水乙醇充分接触囊壁。结果32例患者手术后,30例完全消失,2例缩小达85%,有效率100%。结论CT引导下肾囊肿、卵巢囊肿穿刺硬化剂治疗方法简便、创伤小、痛苦小、恢复快、费用低、疗效高、并发症少,是一种非常有价值的治疗方法。     

多层螺旋CT导向下经皮肾穿刺硬化治疗肾囊肿的临床价值

目的：探讨多层螺旋CT（MSCT）导向下经皮肾穿刺硬化治疗肾囊肿的方法及疗效。方法：经MSCT或MRI诊断的91例107个肾囊肿在MSCT导向下经皮穿刺抽吸、冲洗后注入无水乙醇（99.7%）,注入量为抽出囊液量的25%~30%。须多次抽吸冲洗,直至抽出液清亮。术后螺旋CT跟踪随访1年,评价其疗效。结果：本组107个囊肿穿刺成功率100%,其中71个囊肿在治疗后消失,34个囊肿较治疗前缩小,2个囊肿未见改变。治疗有效率98.1%。所有病例均未出现严重并发症。结论：MSCT引导下经皮肾穿刺硬化治疗肾囊肿是一种安全有效的治疗方法,有重要的临床应用价值。     

CT导引下穿刺注射无水乙醇治疗肾囊肿

目的　评估CT导引经皮穿刺肾囊肿注射无水乙醇治疗的临床经验。方法　 4 4 5例 5 10个肾囊肿于CT导引下经皮穿刺肾囊肿抽液后注射无水乙醇治疗 ,4 4 5例中 385例为单发肾囊肿 ,5 3例多发肾囊肿 ,7例多囊肾。囊肿直径为 1.9～ 13.5cm。用 18～ 2 1G抽吸针穿刺抽吸 ,抽出囊液量为 3～780ml。注入 99.7%乙醇 ,乙醇量以抽出囊液的 2 5 %为合适。结果　本组 396例 (42 7个囊肿 )用CT扫描或超声检查随访 ,随访时间为 3个月到 1年以上 ,单发肾囊肿疗效为 97% ,其中囊腔消失为 82 % ,多发肾囊肿疗效为 95 % ,其中囊腔消失为 79% ,多囊肾疗效为 6 7%。并发症为局部疼痛 (2 8例 ) ,血尿 (4例 ) ,无严重并发症出现。结论　CT导引经皮穿刺肾囊肿乙醇治疗对单发肾囊肿和多发囊肿是一种有价值的治疗方法     

CT引导下肾囊肿穿刺硬化剂治疗的评价

目的 :分析影响CT导引下穿刺硬化剂治疗肾囊肿疗效的因素和预防并发症的方法。方法 :对 96例 13 5个肾囊肿行CT导引下无水乙醇 (纯度 99.7% )硬化治疗 ,囊肿直径 2 .8～ 12 .0cm ,用 2 0G抽吸针穿刺 ,抽液后注入无水乙醇 ,注入量为抽出液的 2 5 .0 %。留置 15min后抽出注入的无水乙醇 ,重新注入少量无水乙醇保留。对于囊液大于 3 0 0ml的囊肿则多次冲洗 ,直至抽出液清亮。结果 :该组随访 5 1例 ,有效率 94.1% ,囊肿消失率 84.3 % ,无严重并发症发生。结论 :CT导引下穿刺硬化剂治疗肾囊肿方法简便 ,疗效好 ,并发症少 ,是一种非常有价值的治疗方法。     

CT导引下卵巢巧克力囊肿穿刺硬化剂治疗的临床应用

目的 探讨CT导引下卵巢巧克力囊肿穿刺硬化剂治疗的临床应用价值.方法 在CT导引下,经皮穿刺囊肿,针尖位置满意后开始抽吸囊液,囊液抽尽注入抽出量25.0%的无水乙醇,保留10～15 min后抽出,然后注入5～10 ml无水乙醇保留.结果 16例中总有效率100%,其中14例囊腔完全消失,2例囊腔缩小达85%～90%.结论 CT导引下卵巢巧克力囊肿治疗方法 简便,疗效可靠,值得临床应用推广.     

2种硬化剂在单纯性肝肾囊肿硬化治疗中的对比研究

目的:对超声引导下单纯性肝肾囊肿穿刺注射新型硬化剂和无水乙醇治疗的疗效进行对比研究。方法:对32例患者36个肝肾囊肿(18例肝囊肿,14例18个肾囊肿)经超声引导抽净囊液后,注入适量新型硬化剂1%聚桂醇注射液(国药准字H20080445),并留置囊内,观察治疗过程中发生的不良反应、患者耐受程度,6月跟踪统计有效率;并与我院采用传统无水乙醇硬化剂治疗的肝肾囊肿统计数据进行对比。结果:32例36个囊肿均一次穿刺成功,按1/10～1/4的比例注入新型硬化剂并保留囊内,患者耐受性良好,无刺激性疼痛和醉酒症状,治疗后1周内,9例患者诉侧腹轻微胀痛,间断低热2 d,未经特殊处理自行消失,无严重不良反应。6月复查33例全部消失,3个囊肿缩小2/3以上,有效率达100%,长期疗效仍在跟踪中。采用传统无水乙醇作为硬化剂注射治疗肝肾囊肿20例(12例肝囊肿,8例肾囊肿),抽净囊液后,按1/4～1/3比例注入无水乙醇,注射时均有短暂刺激性疼痛,18例出现面红、心跳加快、口干、恶心呕吐等醉酒症状。6月复查15例完全消失,5例缩小2/3以上。结论:新型硬化剂聚桂醇治疗肝。肾囊肿疗效与传统无水乙醇硬化治疗一致,但它留置体内,无刺激性剧痛,无醉酒症状,操作简单,不良反应少,患者耐受性好,优于无水乙醇,有望在肝肾囊肿的硬化治疗中成为无水乙醇的替代物。     

肾囊肿的穿刺硬化剂治疗（附235例报告）

目的：总结ＣＴ导引下穿刺硬化剂治疗肾囊肿的经验。材料与方法：２３５例２７０个肾囊肿经皮穿刺抽吸酒精治疗，其中１８６例为单纯肾囊肿，４４例多发囊肿，５例多囊肾。囊肿大小直径为１．９～１３．５ｃｍ。用１９～２１Ｇ抽吸针穿刺抽吸，抽出囊液为３～７８０ｍｌ。注入９９．７％无水酒精，酒精量以抽出囊液的２５．０％为合适。结果：本组随访病例９７例（１０６个肾囊肿），随访时间为３个月以内到１年以上，单纯囊肿疗效为９７．１％，其中囊腔消失为７２．１％；多发囊肿和多囊肾的疗效为７６．３％，其中囊肿消失为３６．８％。并发症为局部疼痛（６．４％），无严重的并发症。结论：ＣＴ导引下经皮穿刺抽吸硬化剂治疗肾囊肿是一种安全、并发症低、疗效高的有价值的治疗方法。     

CT引导下穿刺注射硬化剂治疗卵巢囊肿61例分析

CT引导下的囊肿抽吸和乙醇硬化治疗已成为肝囊肿和。肾囊肿的首选治疗方法,而卵巢囊肿的硬化剂治疗临床报道较少。2010年1月至2012年6月,我科利用CT下引导经皮穿刺注射硬化剂治疗卵巢囊肿患者61例,效果满意,报告如下。     

CT导向下肾囊肿的穿刺硬化治疗

目的 评价CT导向下经皮穿刺无水乙醇注射治疗肾囊肿的临床应用价值。资料与方法 16例24个肾囊肿，其中单纯性肾囊肿10例，肾盂旁囊肿2例，多囊肾4例，在CT导向下行穿刺无水乙醇硬化治疗，分析其并发症，并追踪观察其疗效。结果 16例中，24个囊肿顺利完成穿刺硬化治疗，无严重并发症发生，对18个囊肿术后追踪观察3个月-1年，0-Ⅲ级囊肿疗效个数分别为1（5.6%)，2（11.1%),3(16.7%)和12（66.7%)，临床症状缓解率为81.8%(9/11)。结论 CT导向下经皮肾囊肿穿刺无水乙醇硬化治疗是一种安全有效的治疗方法。     

超声引导下经皮介入治疗单纯肝肾囊肿

目的：观察ＣＯ２与无水酒精作为囊肿固定剂的疗效，比较肝、肾囊肿经介入治疗疗效差别。２２例单纯囊肿，其中肝囊肿１４例，肾囊肿８例，采用经皮穿刺抽吸囊液后，注入固定剂ＣＯ２或无水酒精１￣３次，随访２￣２９个月。结果：２２例２２个囊肿均获得不同程度的好转，占６２．５％。肾囊肿８例均一次治疗后最大直径在随访期间内未超过２ｃｍ，明显好转率为１００％。而肝囊肿１４例中仅５例一次治疗明显好转，占３５．７％。结论     

Percutaneous treatment of hepatic cysts by aspiration and sclerotherapy

We treated 35 patients who had hepatic cysts (30 congenital cysts, 5 hydatid cysts) with percutaneous puncture and sclerotherapy. After puncture and drainage of the cyst, a 95% alcohol solution was instilled as sclerosing agent into the cystic cavity. In all the patients, cyst puncture and drainage was successful. Follow-up in all cases was at least 12 months. In three uncooperative patients, cysts recurred due to incomplete sclerosis of the lining epithelium of the cyst wall. No major complications were encountered in all cases. All congenital cysts were treated on an outpatient basis. Patients with hydatid cyst were hospitalized for 48 h after puncture and aspiration. In our opinion, percutaneous drainage and sclerosis of congenital hepatic cysts can be considered an effective alternative to surgical treatment.     

经皮插管硬化治疗卵巢囊肿

目的 探讨经皮穿刺插管硬化治疗卵巢囊肿的临床价值。方法 在CT引导下经皮穿刺卵巢囊肿,在同轴套管针内插入4F多侧孔猪尾巴导管,用无水乙醇硬化治疗64例76个卵巢囊肿。其中单纯性囊肿48个、巧克力囊肿28个。结果 64例卵巢囊肿穿刺成功率100％,58例（占90、6％）治愈,6例（占9、4％）疗效显著,总有效率为100％,未发生严重并发症。结论 穿刺插管法硬化治疗卵巢囊肿是硬化彻底、安全实用、疗效可靠的方法。     

一次CT导引下置双针穿刺硬化治疗双肾多发肾囊肿的应用体会

目的 探讨一次CT导引下于左右两侧肾区分别置针进行穿刺抽吸、注射硬化剂治疗肾囊肿的应用价值.方法 在一次CT导引下分别于脊柱两侧肾区内确定穿刺点、设计穿刺路径,分别给予交替穿刺、抽吸、冲洗、保留乙醇等治疗步骤,对19例多发肾囊肿进行硬化治疗.结果 通过对19例两侧多发肾囊肿患者同时进行硬化治疗的时间统计,最短延长20 ...     

Sclerotherapy of renal cysts using acetic acid: a comparison with ethanol sclerotherapy

This study compared percutaneous sclerotherapy using 50% acetic acid with that using 99% ethanol for patients with simple renal cysts. The study included 72 simple renal cysts in 64 patients (male/female ratio = 31/33; age range, 31-75 years). Under fluoroscopic guidance, the cyst fluid was aspirated completely. Sclerotherapy was then performed using 50% acetic acid for 32 cysts and 99% ethanol for 40 cysts. The volumes of each renal cyst before and after sclerotherapy were compared using ultrasonography or CT. Medical records were reviewed to analyse any complications. The mean follow-up period was 21.5 months (range, 3-75 months). The mean remnant volume of the cyst after sclerotherapy was 2.6% of the initial volume in the acetic acid group and 14.0% in the ethanol group. The rates of complete remission, partial remission and treatment failure were 90.6%, 9.4% and 0%, respectively, in the acetic acid group, and 60.0%, 30.0% and 10.0%, respectively, in the ethanol group. There were no complications related to sclerotherapy in either group. In conclusion, acetic acid is a safe and effective sclerosing agent, with clinical results superior to those of ethanol, and is an alternative to ethanol for sclerotherapy of renal cysts.     

Abdominal hydatid disease: long-term results of percutaneous treatment

Purpose: To evaluate the effectiveness of percutaneous treatment under sonographic guidance in abdominal hydatid cysts.

Material and Methods: Fifty-two hydatid cysts in 33 patients were treated using a percutaneous approach under sonographic guidance. Forty-five cysts were located in the liver, 6 in the spleen, and 1 in the pancreas. Forty-nine cysts were type I, and 3 were type II. Thirty-one cysts in 15 patients were treated with puncture and aspiration of the contents, injection of hypertonic saline solution, and respiration (PAIR); 15 cysts in 14 patients were treated with puncture, aspiration of cyst contents, injection of hypertonic saline solution, drainage, and injection of sclerosing agent (PAIDS); and 6 cysts in 4 patients were treated with puncture, aspiration of cyst contents, injection of sclerosing agent, and re-aspiration (mPAIDS). Hypertonic saline or alcohol was used as a scolicidal agent. The follow-up period was between 17 and 53 months.

Results: A decrease in the dimensions of the cysts, solidification of the contents, and irregularity in the walls of cysts, all of which were considered signs of cure, were found in all patients. Recurrence was observed in one case and anaphylaxis in one.

Conclusion: Percutaneous treatment of abdominal hydatid cysts is a safe, easily applicable, well-tolerated, and effective method.